While the latest set of interim vaccine results from Oxford University and AstraZeneca include an efficacy score of 70%, significantly lower than the results of competitors, the new vaccine bears other advantages. Phase III interim analysis of data from the Oxford University and AstraZeneca vaccine candidate AZD1222 trial has revealed that the vaccine has an efficacy of 70.4% in an average of two separate dosing regimens. The efficacy data spans 23,000 participants and 131 accrued COVID-19 cases from the UK and Brazil. The dosing regimen offering the highest efficacy of 90% involves the administration of a half dose followed a...
To view this content, please register now for access
Become a member of BioTechniques for FREE to receive:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!